SLS、IBIO和ALDX均为上市前涨幅股

2024-04-03 20:53

Gainers: ARCA biopharma (ABIO) +91% to merge with Oruka Therapeutics in all-stock transaction.
LAMF Global Ventures (LGVC) +85% approve business combination with Nuvo Group
Helius Medical Technologies (HSDT) +29% signs partnership with Lovell Government Services.
Vanda Pharmaceuticals (VNDA) +26% stock jumps as FDA approves Fanapt tablets for bipolar disorder.
VivoPower International (VVPR) +20%.
Australian Oilseeds Holdings (COOT) +19%.
XTI Aerospace (XTIA) +19%.
LENZ Therapeutics (LENZ) +18% gains as eye therapy succeeds in late-stage trial.
Addex Therapeutics (ADXN) +14% Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
5E Advanced Materials (FEAM) +13% Commences Commercial Production At 5E Boron Americas Complex.
Sight Sciences (SGHT) +12% Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Foresight Autonomous Holdings (FRSX) +11% Elbit Systems will Deploy Foresight's Breakthrough Technology with Order from Leading Defense Customer
Cal-Maine Foods (CALM) +6%.
SELLAS Life Sciences Group (SLS) +6%.
iBio (IBIO) +7%.
ATAI Life Sciences (ATAI) +6%.
Dave & Buster's Entertainment (PLAY) +6%.
Aldeyra Therapeutics (ALDX) +6%.
Cidara Therapeutics (CDTX) +6%.
Identiv (INVE) +5% to sell its assets to Vitaprotech for $145M

More on premarket gainers & stock